# Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

> **NCT05259319** · PHASE1 · UNKNOWN · sponsor: **Centre Georges Francois Leclerc** · enrollment: 92 (estimated)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer
- Metastatic Bladder Cancer
- Metastatic Renal Cell Carcinoma
- Metastatic Head and Neck Cancer

## Interventions

- **DRUG:** Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]
- **DRUG:** Tiragolumab
- **RADIATION:** Stereotactic body radiation therapy (SBRT)

## Key facts

- **NCT ID:** NCT05259319
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-05
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-05
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259319, "Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05259319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*